Close Menu

NEW YORK – Daiichi Sankyo and Goustave Roussy have entered into a multi-year collaboration to study and develop two of Daiichi's lead DXd antibody drug conjugates, DS-1062 and patritumab deruxtecan, in lung and breast cancer indications and look for biomarkers of response and resistance.

Under the terms of the agreement, Daiichi will provide funding and support to Gustave Roussy for clinical, translational, and preclinical studies involving these two agents.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.


NTRK fusions are oncogenic drivers in a variety of tumors.

Sponsored by

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Sponsored by

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.


In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.